基于生物信息学分析HDAC8在结肠癌中的临床意义及其与免疫浸润的关系

doi:10.3877/cma.j.issn.1674-0793.2024.04.007

目的

探讨组蛋白乙酰化修饰基因HDAC8对结肠癌患者预后的影响，及其与免疫浸润的相关性。

方法

采用单因素和多因素Cox回归、Kaplan-Meier曲线分析HDAC8与结肠癌患者预后的相关性；采用GO富集分析探索HDAC8在结肠癌中的潜在作用；采用ESTIMATE算法、CIBERSORT、ssGSEA分析HDAC8与结肠癌肿瘤免疫浸润的相关性。

结果

聚类分析将结肠癌患者分为三个亚组，其中Group3的患者预后差。Group3中高表达基因HDAC8与肿瘤免疫微环境和患者预后差相关。HDAC8在结肠癌组织中表达上调（P<0.001），主要与免疫应答、防御反应等生物学过程相关。HDAC8高表达组中ESTIMATE评分、基质评分和免疫评分较低，而肿瘤纯度较高（P<0.01）。HDAC8与树突状细胞、CD8⁺T细胞、B细胞和NK细胞等多种免疫细胞浸润呈负相关。HDAC8高表达组中树突状细胞活性、成熟评分较低，CD8⁺T细胞幼稚评分较高，而杀伤功能、耗竭功能评分较低（P<0.001）。

结论

HDAC8的表达与结肠癌患者预后密切相关，其可能通过介导树突状细胞的成熟障碍影响T细胞成熟，参与形成肿瘤组织中失能的免疫微环境，调控结肠癌的发生与发展。

关键词: 结肠肿瘤, 组蛋白乙酰化修饰, HDAC8, 生物信息学, 预后, 免疫浸润

Objective

To investigate the prognosis, expression of histone acetylation and its correlation with immune infiltration in colon cancer.

Methods

Univariate and multivariate Cox regression and Kaplan-Meier curve were utilized to evaluate the relationship between HDAC8 gene expression and prognosis of COAD patients. GO enrichment analysis was performed for the potential role of HDAC8 in colon cancer. The connection between HDAC8 and tumor infiltrating immune cells was analyzed based on ESTIMATE, CIBERSORT and ssGSEA.

Results

Cluster analysis results showed that three acetylation modification subgroups were identified. The highly expressed HDAC8 in Group3 was upregulated in colon cancer tissues and associated with poor prognosis. HDAC8 was closely associated with tumor immune microenvironment such as stromal, immune scores and tumor purity. HDAC8 expression indicated significantly negative correlations with the infiltration of cells such as dendritic cells, CD8⁺ T cells, B cells and NK cells. It was negatively correlated with the activation, maturation, cytotoxicity and costimulatory scores of dendritic cell and CD8⁺ T cells.

Conclusions

The expression of HDAC8 is closely related to the prognosis of colon cancer patients. It may affect the maturation of dendritic cells and T cells, participate in the formation of dysfunctional immune microenvironment in tumor tissues, and regulate the development of colon cancer.

Key words: Colonic neoplasms, Histone acetylation, HDAC8, Bioinformatics, Prognosis, Immune infiltration

图1 结肠癌患者中组蛋白乙酰化修饰基因的聚类分析　A为一致性累计分布函数图；B为CDF曲线下面积变化图；C为K=3时的一致性聚类热图；D为三个聚类亚组的结肠癌患者组蛋白乙酰化修饰相关基因的表达情况及临床病例特征热图

图2 各亚组间生存分析及Group3中高表达水平基因与结肠癌微环境细胞的相关性　A为三个亚组结肠癌患者生存分析比较；B为Group3中高表达基因与基质评分、免疫评分、ESTIMATE评分和肿瘤纯度的相关性；C为Group3中高表达基因与免疫细胞浸润程度的相关性

图3 筛选与结肠癌患者预后相关的组蛋白乙酰化修饰基因　A为KAT2A与结肠癌患者无病进展生存期的关系；B为KAT2A与结肠癌患者无进展生存期的关系；C为HDAC8与结肠癌患者无病进展生存期的关系；D为HDAC8与结肠癌患者无进展生存期的关系；E为HDAC8及结肠癌患者病例特征与生存时间的单因素Cox回归分析森林图；F为多因素Cox回归分析森林图；G为基于TCGA数据库比较HDAC8在正常组织和结肠癌组织中的表达水平；H为基于GSE44076数据集比较HDAC8在正常组织和结肠癌组织中的表达水平；I为基于GSE110224数据集比较HDAC8在正常组织和结肠癌组织中的表达水平

图4 HDAC8的GO富集分析

图5 HDAC8与结肠癌中免疫浸润的相关性　A为HDAC8高表达组和低表达组间基质评分、免疫评分、ESTIMATE评分和肿瘤纯度的比较；B为基于CIBERSORT比较HDAC8高-低表达组间的免疫细胞浸润程度；C为基于ssGSEA比较HDAC8高-低表达组间的免疫细胞浸润程度。^*P<0.05；^**P<0.01；^***P<0.001

图6 HDAC8与结肠癌中免疫浸润的相关性散点图　A为HDAC8与免疫细胞浸润程度的相关性；B为HDAC8高低组间T细胞相关功能评分差异；C为HDAC8高低组间幼稚T细胞浸润差异；D为HDAC8高低组间树突状细胞相关功能评分差异；^**P<0.01；^***P<0.001

[1]	Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49.
[2]	Huang J, Lucero-Prisno DE 3rd, Zhang L, et al. Updated epidemiology of gastrointestinal cancers in East Asia[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(5): 271-287.
[3]	Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34(1): 10-32.
[4]	Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN[J]. Gut, 2023, 72(2): 338-344.
[5]	Wang P, Wang Z, Liu J. Role of HDACs in normal and malignant hematopoiesis[J]. Mol Cancer, 2020, 19(1): 5.
[6]	Palamaris K, Tzimou LM, Levidou G, et al. Histone deacetylases (HDACs): promising biomarkers and potential therapeutic targets in thymic epithelial tumors[J]. Int J Mol Sci, 2023, 24(5): 4263.
[7]	Huang C, Shu Y, Zhu Y, et al. Discovery of non-substrate, environmentally sensitive turn-on fluorescent probes for imaging HDAC8 in tumor cells and tissue slices[J]. Bioorg Med Chem, 2022, 68: 116821.
[8]	Kim JY, Cho H, Yoo J, et al. Pathological role of HDAC8: cancer and beyond[J]. Cells, 2022, 11(19): 3161.
[9]	Yang W, Feng Y, Zhou J, et al. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma[J]. Sci Transl Med, 2021, 13(588): eaaz6804.
[10]	Tang X, Li G, Su F, et al. HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration[J]. Nucleic Acids Res, 2020, 48(6): 2912-2923.
[11]	Blaszczak W, Liu G, Zhu H, et al. Immune modulation underpins the anti-cancer activity of HDAC inhibitors[J]. Mol Oncol, 2021, 15(12): 3280-3298.
[12]	Amin SA, Khatun S, Gayen S, et al. Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?[J]. Eur J Med Chem, 2023, 258: 115594.
[13]	Kim JY, Cho H, Yoo J, et al. HDAC8 deacetylates HIF-1α and enhances its protein stability to promote tumor growth and migration in melanoma[J]. Cancers (Basel), 2023, 15(4): 1123.
[14]	Wang F, Jin Y, Wang M, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: A randomized phase 2 trial[J]. Nat Med, 2024, 30(4): 1035-1043.
[15]	Zhao C, Chen D, Suo F, et al. Discovery of highly potent HDAC8 PROTACs with anti-tumor activity[J]. Bioorg Chem, 2023, 136: 106546.
[16]	Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer[J]. Pharmacol Ther, 2021, 221: 107753.
[17]	Pittet MJ, Di Pilato M, Garris C, et al. Dendritic cells as shepherds of T cell immunity in cancer[J]. Immunity, 2023, 56(10): 2218-2230.
[18]	Heras-Murillo I, Adán-Barrientos I, Galán M, et al. Dendritic cells as orchestrators of anticancer immunity and immunotherapy[J]. Nat Rev Clin Oncol, 2024, 21(4): 257-277.

[1]	丁丁, 杨云川, 马翔, 马中正, 霍俊一, 周磊. 术前C-反应蛋白-白蛋白-淋巴细胞比值在肝细胞癌预后中的价值评估[J]. 中华普通外科学文献(电子版), 2024, 18(04): 261-265.
[2]	孙建娜, 孔令军, 任崇禧, 穆坤, 王晓蕊. 266例首诊Ⅳ期乳腺癌手术患者预后分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(05): 502-505.
[3]	袁庆港, 刘理想, 张亮, 周世振, 高波, 丁超, 管文贤. 尿素-肌酐比值（UCR）可预测结直肠癌患者术后的长期预后[J]. 中华普外科手术学杂志(电子版), 2024, 18(05): 506-509.
[4]	黄福, 王黔, 金相任, 唐云川. VEGFR2、miR-27a-5p在胃癌组织中的表达与临床病理参数及预后的关系研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(05): 558-561.
[5]	崔宏帅, 冯丽明, 东维玲, 韩博. 腹腔镜右半结肠癌D3根治术+IGLN清扫术治疗局部进展期结肠肝曲癌的临床效果研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(05): 566-569.
[6]	丁志翔, 于鹏, 段绍斌. 血浆BRAF基因检测对腹腔镜右半结肠癌D3根治术中行幽门淋巴结清扫的指导价值[J]. 中华普外科手术学杂志(电子版), 2024, 18(05): 570-573.
[7]	王维花, 王楠, 乔庆, 罗红. 完全腹腔镜右半结肠癌切除术两种腔内消化道重建方案对比研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(05): 574-577.
[8]	李晓鸥, 杨鹤鸣, 王国栋, 林海冠, 杨建武. 不同入路腹腔镜左半结肠癌根治术治疗效果对比[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 377-380.
[9]	蔡大明, 陆晓峰, 王行舟, 王萌, 刘颂, 夏雪峰, 沈晓菲, 杜峻峰, 管文贤. 三级淋巴结构在胃神经内分泌瘤中的预后价值及预后预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 401-405.
[10]	达热拜·热达提, 刘林, 赵为民, 孟涛, 雷程, 金博, 毕建军, 李新宇, 王海江. 中低位直肠癌新辅助放化疗后侧方淋巴结清扫术的临床观察[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 415-418.
[11]	李勇, 彭天明, 王倩倩, 陈育纯, 蒲小勇, 刘久敏. 基于失巢凋亡相关基因的膀胱癌预后模型构建及分析[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 331-339.
[12]	钱承博, 殷虎明, 邱峰, 侯建全, 黄玉华, 魏雪栋. 高龄患者行腹腔镜膀胱根治W形回肠新膀胱术的临床价值与风险评估[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 346-352.
[13]	张斌, 孙代宇, 胡昕, 韩菲, 李久明, 李功雨, 吴伟力, 冯宝富, 彭国辉. 评分系统预测不同经验手术者输尿管软镜术后结石清除率准确性的比较研究[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 353-360.
[14]	刘中文, 刘畅, 高洋, 刘东, 林世庆, 杨建华, 赵福义. 尿液microRNA-326与腹腔镜根治性膀胱切除术治疗膀胱癌患者预后的相关性研究[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 386-391.
[15]	杨秀君, 崔梦莹, 刘水, 盛基尧, 张丹. 基于SEER数据库胰头部胰腺神经内分泌癌患者预后列线图构建与验证[J]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 520-525.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Analysis of clinical significance of HDAC8 in colon cancer and its relationship with immune infiltration based on bioinformatics

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Analysis of clinical significance of HDAC8 in colon cancer and its relationship with immune infiltration based on bioinformatics